metabolic associated fatty liver disease, MAFLD
Conditions
Interventions
Group not receiving comprehensive intervention plan of traditional Chinese Medicine :Including those who only received Western medical treatment (taking silibinin, bicyclol, polyene phosphorylcholine,
TCM Integrated Intervention Program Group:(1) Chinese herbal decoction: According to TCM syndrome differentiation and treatment, choose Gegen Qinlian Decoction, Sanshu Yishan Decoction or addition and
Sponsors
Hubei Provincial Hospital of traditional Chinese Medicine
Eligibility
Sex/Gender
All
Age
10 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Diagnostic criteria The diagnosis of MAFLD[1] is based on hepatic steatosis (detected by liver histology, imaging, or non-invasive biomarkers) and the presence of at least one of the following three criteria, including: (1) Overweight or obese; (2) Type 2 diabetes (T2DM); (3) There are at least two risk factors for abnormal metabolism: a. Waist circumference: Asian men = 90cm, women = 80cm b. Blood pressure: =130/85mmHg or receive specific drug treatment c. Triglyceride: =1.7mmol/L or receive specific drug treatment d. High-density lipoprotein cholesterol: male 2mg/L 2. Inclusion criteria 1) Age: 10-65 years old, gender is not limited; 2) Meet the above diagnostic criteria for metabolic-associated fatty liver disease (MAFLD); 3) Good compliance, willing to abide by the principle of follow-up; 4) Agree to sign the informed consent; 5) Only those who meet all the above conditions can participate in this study.
Exclusion criteria
Exclusion criteria: Exclusion criteria 1) Serious diseases of the heart, liver, lung, kidney, brain, blood, neuropsychiatric system, etc., whose disease is not under control; 2) Diagnose patients with liver fibrosis, liver cirrhosis, alcoholic liver disease, immune liver disease and drug-induced liver disease; 3) Patients with various malignant tumors; 4) Patients who have received fatty liver related diagnosis and treatment within 1 month; 5) Pregnant or lactating women; 6) The researcher believes that it is not suitable to participate in this research; Anyone who meets any of the above criteria cannot participate in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| LSM;ALT;PLT;AST;Liver histopathology score; | — |
Secondary
| Measure | Time frame |
|---|---|
| FBG;INS;CEA; | — |
Countries
China
Contacts
Public ContactMingzhong Xiao
Hubei Provincial Hospital of traditional Chinese Medicine
Outcome results
None listed